Merck Seeks To Build RNAi Muscle Through Artemis Partnership
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal calls for Germany-based Artemis to construct shRNA mouse models.
You may also be interested in...
AstraZeneca Gains Access To Silence siRNA Technology For Respiratory Targets
Company will use siRNA molecules against up to five targets in deal valued at up to $400 million.
AstraZeneca Gains Access To Silence siRNA Technology For Respiratory Targets
Company will use siRNA molecules against up to five targets in deal valued at up to $400 million.
Yes, Sirna: Merck Inks $1.1 Bil. Deal For RNAi Firm
Merck continues acquisition spurt with purchase of San Francisco biotech.